Revisiting the Carbon Footprint of Single‐Use Technologies in Biomanufacturing: A Bottom‐Up Analysis Reveals a Paradigm Shift
バイオ製造におけるシングルユース技術の炭素フットプリントの再考：ボトムアップ分析が明らかにするパラダイムシフト (AI 翻訳)
Jan Reiners, Katharina Bruno-Thakur, Daina Romeo, Weronika Kuśmierczyk, Ferdinand Stückler
🤖 gxceed AI 要約
日本語
本研究は、バイオ医薬品製造におけるシングルユース技術（SUT）の炭素フットプリントを、2000Lスケールで物理分解に基づく詳細なボトムアップ分析により再評価。SUTは従来、水・エネルギー節約でステンレス鋼（SST）より持続可能とされたが、実際のCO2排出量は大幅に高く、フィルターやバッグが主要排出源であることが判明。電力グリッドの脱炭素化によりSSTプロセスの排出量が低下し、SUTとSSTを組み合わせたハイブリッド設計が廃棄物と排出を削減できることを示した。
English
This study presents a detailed bottom-up carbon footprint analysis of single-use technologies (SUT) in biopharmaceutical manufacturing at the 2000 L scale, based on physical disassembly. It finds that SUT's CO2 footprint is significantly higher than previously thought, with filters and bags as key hotspots. Due to electricity grid decarbonization, stainless steel (SST) processes can now have lower carbon footprints. Hybrid facility designs combining SUT and SST can reduce plastic waste and emissions.
Unofficial AI-generated summary based on the public title and abstract. Not an official translation.
📝 gxceed 編集解説 — Why this matters
日本のGX文脈において
日本のバイオ医薬品製造でもSUT普及が進むが、本論文はSUTの炭素フットプリントが過小評価されている可能性を指摘。ハイブリッド設計の有効性は、製造業における資源効率向上や廃棄物削減の取り組みと整合する。SSBJや有報でのGHG排出量報告において、製造工程の詳細なカーボンフットプリント分析が重要であることを示す。
In the global GX context
This paper challenges the prevailing assumption that single-use technologies are inherently more sustainable in biopharmaceutical manufacturing. With progressive grid decarbonization, the carbon advantage of SUT over stainless steel diminishes. The findings are critical for the pharmaceutical industry's sustainability strategies and for accurate Scope 1/2/3 reporting under ISSB and CSRD, advocating for hybrid facility designs to reduce emissions and plastic waste.
👥 読者別の含意
🔬研究者:Provides a granular carbon footprint methodology and empirical comparison that can inform life-cycle assessments for biopharma manufacturing and similar process industries.
🏢実務担当者:Offers actionable insights for biopharma companies to optimize facility design by combining SUT and SST to reduce carbon footprint and plastic waste.
🏛政策担当者:Suggests that regulatory frameworks for pharmaceutical sustainability should consider process-level carbon footprints and not assume single-use is always greener.
📄 Abstract（原文）
ABSTRACT The biopharmaceutical industry increasingly relies on single‐use technologies (SUT) for operational flexibility. For a long time, SUT was considered more sustainable than stainless‐steel (SST) systems due to water and energy savings. This study re‐evaluates this paradigm via a detailed bottom‐up analysis of the SUT carbon footprint at the 2000 L scale. Our analysis, based on two real‐world facility case studies (a full‐SUT and a hybrid‐SUT model), shows that the CO2 footprint of SUT is significantly higher than previously assumed. This granular analysis, based on physical disassembly and updated “cradle‐to‐gate” factors, identifies filters and bags as key emission hotspots. A separate comparative analysis also shows that key SST process steps—favored by the progressive decarbonization of electricity grids—can now have a lower carbon footprint than their SUT counterparts. Our data demonstrates that an operationally optimized hybrid facility design, which combines SUT with SST, can significantly reduce plastic waste and associated emissions. These findings compel a reassessment of sustainability strategies in biopharmaceutical manufacturing and highlight the potential of fit‐for‐purpose hybrid models as an effective lever for reducing the ecological footprint.
🔗 Provenance — このレコードを発見したソース
- openalex https://doi.org/10.1002/bit.70297first seen 2026-07-07 04:47:51
🔔 こうした論文の新着を逃したくない方は キーワードアラート に登録（無料・3キーワードまで）。
gxceed は公開メタデータに基づく研究支援データセットです。要約・翻訳・解説は AI 支援で生成されています。 最終的な解釈・検証は利用者が原典資料に基づいて行うことを前提とします。